Hot Features
Überwachen Sie mehrere Echtzeitkurse von führenden Börsen wie NASDAQ, NYSE, AMEX, Bovespa und mehr.
Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug ... Quince Therapeutics, Inc., is a late-stage biotechnology company dedicated to unlocking the power of a patient's own biology for the treatment of rare diseases. The company's Phase 3 lead asset, EryDex, is the first product in development that leverages its proprietary Autologous Intracellular Drug Encapsulation, or AIDE, technology platform, which is a novel drug/device combination that uses an automated process designed to encapsulate a drug into the patient's own red blood cells. Mehr anzeigen
Phase 3 NEAT clinical trial on track with 32 patients enrolled to date with majority of U.S. and European study sites now enrolling patients Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...
Quince Therapeutics, Inc. (Nasdaq: QNCX), a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that...
| Zeitraum † | Änderung | Änderung % | Handelsbeginn | Hoch | Niedrig | Durchsch. Volumen | VWAP | |
|---|---|---|---|---|---|---|---|---|
| 1 | -0.2 | -9.75609756098 | 2.05 | 2.06 | 1.75 | 220907 | 1.88406444 | CS |
| 4 | -0.36 | -16.2895927602 | 2.21 | 2.45 | 1.68 | 281001 | 1.96968446 | CS |
| 12 | 1.0897 | 143.325003288 | 0.7603 | 2.45 | 0.69 | 599908 | 1.43183185 | CS |
| 26 | 1.16 | 168.115942029 | 0.69 | 2.45 | 0.5116 | 360146 | 1.24642263 | CS |
| 52 | 0.78 | 72.8971962617 | 1.07 | 2.45 | 0.5116 | 226835 | 1.20908304 | CS |
| 156 | -10.08 | -84.4928751048 | 11.93 | 14.6 | 0.5116 | 476154 | 2.60102509 | CS |
| 260 | -45.76 | -96.1142617097 | 47.61 | 121.98 | 0.5116 | 459953 | 13.68154864 | CS |
| Keine Diskussionen Gefunden. |
| Neuen Thread Erstellen |
Support: +44 (0) 203 8794 460 | support@advfn.de
Durch das Benutzen des ADVFN Angebotes akzeptieren Sie folgende Allgemeine Geschäftsbedingungen
Premium
